I'm LongbridgeAI, I can summarize articles.SPDR S&P Biotech (XBI) fell 2.02% this week to $162.38, with a weekly amplitude of 5.09%. The fund staged a rally and pulled back: it opened the week lower, hit a weekly high of $169.89 on Tuesday, then drifted lower across the next three sessions to finish Friday at $162.38. The close remains above the 20-day moving average of $160.22 and the 60-day line of $152.47. Average daily volume was 8.34 million shares, about 1.6% below its 60-day median.
The Week
SPDR S&P Biotech (XBI) fell 2.02% this week to $162.38, with a weekly amplitude of 5.09%. The fund staged a rally and pulled back: it opened the week lower, hit a weekly high of $169.89 on Tuesday, then drifted lower across the next three sessions to finish Friday at $162.38. The close remains above the 20-day moving average of $160.22 and the 60-day line of $152.47. Average daily volume was 8.34 million shares, about 1.6% below its 60-day median.
Sector News
The week’s central story was Revolution Medicines’ FDA approval for its pancreatic cancer drug, which sent the stock sharply higher and sparked repricing across small-cap peers. Analysts raised their price targets and put peak sales at $11.5 billion. Halozyme touched a 12-month high as Vise Technologies and Bank of New York Mellon added to positions. Natera announced a national partnership with Susan G. Komen and a companion diagnostic collaboration with Angiex. Moderna slipped on a planned $2 billion private placement, while Twist Bioscience’s CEO sold $6.28 million in shares. On the macro side, Fed official Warsh used Jackson Hole to flag AI-era inflation risks, leaving the rates outlook cautious.
The Week Ahead
Next week opens with a run of manufacturing and jobs data. The Dallas Fed manufacturing index lands Monday, followed on Tuesday by the final S&P Global manufacturing PMI and ISM manufacturing PMI (prior 55.6, forecast 55.2), plus the JOLTS job openings report. Wednesday brings the ADP private payrolls print, factory orders, and weekly EIA crude and Cushing inventory data. These releases will shape rate expectations and risk appetite, with direct implications for rate-sensitive biotech.
In Short
This week showed a split: a high-profile FDA approval lifted select names, but the broader fund still lost 2.02%, suggesting single-stock clinical and regulatory wins have not yet translated into sector-wide upside. On the latest trading day, large-lot money was a net seller while small and medium orders were net buyers. Next week’s manufacturing and employment data could shift rate expectations; stronger prints may pressure biotech valuations even as R&D and partnership activity continues. The key to watch is whether rate expectations and actual flows start moving in the same direction.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.